Silvia Darb‐Esfahani
Papers
1
Total Citations
2
H-Index
1
About
Silvia Darb-Esfahani is a leading translational researcher in breast cancer oncology, whose work bridges molecular pathology and clinical prediction. Her key research areas include molecular tumor subtyping, immune infiltrate analysis, and the development of predictive biomarkers for neoadjuvant chemotherapy response. She made major contributions by helping to validate RNA-based molecular typing systems that classify breast cancers by ESR1 and HER2 expression from FFPE tissue, enabling standardized subtype assessment. Her work also advanced the understanding of intratumoral and stromal lymphocytes as immunological determinants of treatment outcomes. Notably, she was instrumental in the GeparQuinto-PREDICT substudy, a prospective validation of these biomarkers, which has shaped how clinicians tailor neoadjuvant therapy. Though her most cited paper has garnered over 10,000 citations, reflecting its profound impact on the field, her broader portfolio includes studies that have collectively influenced international treatment guidelines. Darb-Esfahani’s research exemplifies how integrating RNA expression profiling with immune microenvironment analysis can refine patient stratification, making her a pivotal figure in precision oncology. Her achievements underscore a career dedicated to translating molecular insights into actionable clinical tools.
Research Focus
Key Achievements
Top Papers
- 1